Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YR-2316
- Development stage
- Preclinical
- Lead developer
- Nanjing Hailing Traditional Chinese Medicine Pharmaceutical Art Technical Research
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
YR-2316 is an inhalation powder (dry powder inhaler) developed by Yangtze River Pharmaceutical Group and its subsidiary Nanjing Hailing Pharmaceutical. In August 2026, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) accepted the Investigational New Drug (IND) application for YR-2316 as a Class 2.2 improved chemical drug. Although the specific molecular target and mechanism of action have not been publicly disclosed by the developer, it is widely anticipated to be developed for respiratory diseases such as chronic obstructive pulmonary disease (COPD) or asthma, representing Yangtze River Pharmaceutical's first entry into the innovative dry powder inhaler space.
- Other names
- YR-2316吸入粉雾剂
Beyond the preview
Go deeper on YR-2316.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YR-2316.